Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
Semin Radiat Oncol. 2011 Apr;21(2):157-66. doi: 10.1016/j.semradonc.2010.11.003.
The growth of functional and metabolically informative imaging is eclipsing anatomic imaging alone in clinical practice. The recognition that magnetic resonance (MR) and positron emission tomography (PET)-based treatment planning and response assessment are essential components of clinical practice and furthermore offer the potential of quantitative analysis being important. Extracting the greatest benefit from these imaging techniques will require refining the best combinations of multimodality imaging through well-designed clinical trials that use robust image-analysis tools and require substantial computer based infrastructure. Through these changes and enhancements, image-based biomarkers will enhance clinical decision making and accelerate the progress that is made through clinical trial research.
功能和代谢性成像的发展正在超越单纯的解剖成像，成为临床实践中的主流。磁共振（MR）和正电子发射断层扫描（PET）为基础的治疗计划和反应评估已被公认为临床实践的重要组成部分，并且具有提供定量分析的潜力。为了从这些成像技术中获得最大的收益，需要通过精心设计的临床试验来优化多模态成像的最佳组合，这些临床试验需要使用强大的图像分析工具和大量的计算机基础设施。通过这些改变和改进，基于图像的生物标志物将增强临床决策，并通过临床试验研究加速进展。
